Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCs for Cerebral Hemorrhagic Stroke
NCT03726814Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Dec 2018
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of endothelial progenitor cells in ischemic stroke, sponsored by Allife Medical Science and Technology. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 1 year. Status: unknown.
02
Drugs
endothelial progenitor cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03726814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726814.